Conditions:   Myeloid Malignancy;   Bone Marrow Failure Syndrome;   Transfusion-dependent Red Blood Cell (RBC) Defect;   Congenital Immunodeficiency;   Metabolic Disease;   Severe Immune Dysregulation
Interventions:   Drug: Alemtuzumab;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine
Sponsors:   University of California, San Francisco;   Christopher Dvorak
Not yet recruiting - verified May 2012

Conditions:   Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myeloproliferative Diseases;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions:   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified April 2012

Condition:   Sickle Cell Disease
Intervention:   Other: Biological: Bone Marrow Transplant
Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012

Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions:   Other: pharmacological study;   Drug: tacrolimus;   Drug: sirolimus;   Biological: anti-thymocyte globulin;   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: bortezomib;   Procedure: allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Hematopoietic Stem Cell Transplantation;   Solid Tumor;   Transplantation, Autologous
Interventions:   Drug: Ifosfamide;   Drug: Etoposide phosphate;   Drug: Mesna;   Biological: Granulocyte colony-stimulating factor;   Drug: Busulfan;   Drug: Melphalan;   Drug: Thiotepa;   Biological: Autologous stem cell infusion;   Radiation: Radiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Acute Myeloid Leukemia;   Acute Leukemia;   Chronic Myelogenous Leukemia;   Malignant Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Lymphocytic Leukemia;   Myeloproliferative Disorder;   Polycythemia Vera;   Myelofibrosis;   Aplastic Anemia
Interventions:   Drug: fludarabine/busulfan;   Drug: fludarabine/ melphalan
Sponsors:   University of Illinois;   University of Illinois
Recruiting - verified September 2011

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Hodgkins Disease;   Non-Hodgkins Lymphoma;   Aplastic Anemia;   Multiple Myeloma;   Myelodysplastic Syndrome
Interventions:   Drug: Busulfan;   Drug: Clofarabine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine
Sponsors:   Texas Oncology Cancer Center;   Texas Oncology Cancer Center
Recruiting - verified December 2011

Conditions:   Disorder Related to Bone Marrow Transplantation;   Leukemia;   Transplantation Infection
Interventions:   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Acute Myelogenous Leukemia;   Refractory Acute Myelogenous Leukemia
Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Radiation: Total body irradiation;   Drug: Cyclophosphamide;   Drug: Levetiracetam;   Drug: Busulfan;   Biological: Umbilical Cord Blood Transplantation;   Biological: Interleukin-2
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011

Condition:   Acute Myeloblastic Leukemia
Interventions:   Drug: Clofarabine/Busulfan x 4;   Procedure: Peripheral blood stem cell transplant
Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   Genzyme;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified November 2011

Condition:   Sickle Cell Disease
Intervention:   Drug: CD34 selected T-cell depleted allogeneic stem cell transplantation
Sponsors:   New York Medical College;   New York Medical College;   Children's Hospital & Research Center Oakland;   Columbia University;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts University;   University of California, San Francisco;   Miltenyi Biotec GmbH;   Otsuka Pharmaceutical Development & Commercialization, Inc.;   FDA Office of Orphan Products Development
Recruiting - verified April 2012

Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Condition:   Lymphoma
Interventions:   Drug: Vorinostat;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Rituximab;   Drug: G-CSF;   Drug: Palifermin
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Myeloma
Interventions:   Drug: Busulfan;   Drug: Melphalan;   Other: Questionnaire;   Drug: G-CSF;   Drug: High Dose Melphalan;   Procedure: Stem cell transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2012

Conditions:   Leukemia;   Lymphoma;   HIV
Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI);   Drug: Fludarabine;   Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012

Conditions:   Leukemia;   Chronic Myelogenous Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Procedure: NK cell infusion:;   Drug: Interleukin-2;   Drug: Anti-Thymocyte Globulin;   Procedure: Allogeneic related Stem Cell Transplant;   Drug: Tacrolimus;   Drug: Methotrexate
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
Interventions:   Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (TBI)
Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
Recruiting - verified June 2011

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention:   Drug: Decitabine plus Fludarabine and Busulfan
Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
Recruiting - verified October 2011

Condition:   Chemotherapy-induced Nausea and Vomiting
Intervention:   Drug: Palonosetron, ondansetron, dexamethasone
Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012

Condition:   Leukemia, Myelocytic, Acute
Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Busulfan and Cyclophosphamide (Bu/Cy);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012

Conditions:   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
Intervention:   Procedure: Allogeneic transplantation
Sponsors:   Scripps Health;   Scripps Health
Recruiting - verified June 2011

Condition:   Congenital Pediatric Disorders
Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
Recruiting - verified August 2011

Condition:   Myeloma
Interventions:   Drug: Palifermin;   Drug: Dexamethasone;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Hematologic Neoplasms
Intervention:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
Recruiting - verified March 2012

Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Busulfan;   Drug: Fludarabine
Sponsors:   West Virginia University;   Mehdi Hamadani;   Georgia Health Sciences University
Recruiting - verified December 2011

Condition:   Lymphoma
Interventions:   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplantation;   Drug: Palifermin
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
Interventions:   Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Drug: Busulfan;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Condition:   Neuroblastoma
Interventions:   Drug: busulfan;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: isotretinoin;   Drug: melphalan;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: iobenguane I 131
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified April 2012

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: anti-thymocyte globulin;   Drug: azacitidine;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Condition:   Multiple Myeloma
Interventions:   Drug: busulfan, melphalan and fludarabine;   Drug: busulfan, melphalan and fludarabine
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Otsuka America Pharmaceutical
Recruiting - verified January 2012

Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified December 2011

Conditions:   Non-Hodgkin's Lymphoma;   CNS Lymphoma
Intervention:   Procedure: High-dose chemotherapy with autologous stem cell transplant
Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Genentech;   Otsuka America Pharmaceutical;   Dana-Farber Cancer Institute
Recruiting - verified April 2012

Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia
Interventions:   Procedure: double-unit umbilical cord blood transplantation;   Other: cytogenetic analysis;   Procedure: bone marrow aspiration;   Other: fluorescence in situ hybridization;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: anti-thymocyte globulin;   Drug: methylprednisolone;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
Recruiting - verified January 2012

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Busulfan
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified March 2012

Conditions:   Mucopolysaccharidosis;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy (ALD);   Globoid Cell Leukodystrophy (GLD);   Krabbe Disease;   Metachromatic Leukodystrophy (MLD);   Sphingolipidoses;   Peroxisomal Disorders
Interventions:   Drug: Campath-1H;   Drug: Cyclophosphamide;   Drug: Busulfan;   Procedure: Allogeneic stem cell transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
Intervention:   Other: Hematopoetic Stem Cell Transplant using Reduced Intensity Conditioning Regimen
Sponsors:   Children's Hospital of Philadelphia;   Children's Hospital of Philadelphia
Recruiting - verified May 2012

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified May 2012

Conditions:   Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30
Sponsors:   Columbia University;   Columbia University
Recruiting - verified October 2011

Conditions:   Leukemia;   Lymphoma;   Allogeneic Haematopoietic Stem Cell Transplantation;   Acute Lymphoblastic Leukemia
Interventions:   Drug: Busulfan;   Drug: Clofarabine;   Drug: Thymoglobulin;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome
Intervention:   Other: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine. CD34+ T-cell depleted peripheral blood stem cell transplant
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Hospital Boston;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Rockefeller University;   Fred Hutchinson Cancer Research Center
Recruiting - verified November 2011

Conditions:   Acute Myeloid Leukemia;   Lymphoblastic Leukemia;   Acute Leukemia;   Non Hodgkins Lymphoma;   Chronic Myeloid Leukemia
Intervention:   Radiation: Intensity modulated total marrow irradiation
Sponsors:   University of Illinois;   University of Illinois
Recruiting - verified August 2011

Condition:   Congenital Pediatric Disorders
Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
Recruiting - verified August 2011

Conditions:   Bone Marrow Transplantation;   Sickle Cell Disease
Intervention:   Drug: fludarabine
Sponsors:   Emory University;   Emory University
Recruiting - verified November 2011

Conditions:   Leukemia;   Lymphoma;   Myeloma
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath;   Procedure: Stem Cell Transplant
Sponsors:   University of Chicago;   University of Chicago
Recruiting - verified June 2011

Condition:   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation
Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Condition:   Fanconi Anemia
Intervention:   Device: CliniMACs device
Sponsors:   Medical College of Wisconsin;   Medical College of Wisconsin;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2012

Conditions:   Stem Cell Transplantation;   Leukemia;   Lymphoma
Interventions:   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Busulfan;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin (ATG);   Drug: G-CSF (Filgrastim)
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified February 2012

Condition:   Acute Myelogenous Leukemia
Intervention:   Drug: Etoposide, Cytarabine, Busulfan
Sponsors:   University of California, San Francisco;   University of California, San Francisco
Recruiting - verified February 2012

Conditions:   Stem Cell Transplantation;   Leukemia
Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: Thymoglobulin;   Drug: Azacitidine;   Procedure: Stem Cell Transplant
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified December 2011

Conditions:   Hematologic Malignancies;   Graft vs Host Disease
Interventions:   Procedure: reduced intensity, matched related donor stem cell transplant;   Drug: tacrolimus (standard GVHD prophylaxis);   Drug: mycophenolate (standard GVHD prophylaxis);   Drug: vorinostat
Sponsors:   University of Michigan Cancer Center;   Pavan Reddy, MD
Recruiting - verified February 2012

Conditions:   MDS;   Leukemias;   Lymphomas
Intervention:   Drug: Drug: busulfan, Cyclophosphamide, Total Body Irradiation
Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Otsuka Pharmaceutical Co., Ltd.;   National Center for Research Resources (NCRR)
Recruiting - verified January 2012

Condition:   Severe Osteopetrosis
Interventions:   Procedure: Stem Cell Transplantation;   Drug: Conditioning for transplantation-donor graft;   Radiation: Total Lymphoid Irradiation;   Drug: Conditioning for cord blood transplant
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012

Conditions:   Non-Hodgkin's Lymphoma;   Hodgkins Disease
Interventions:   Drug: Fludarabine and Busulfan;   Drug: Fludarabine, Busulfan and ATG
Sponsors:   Columbia University;   Columbia University;   Duke University
Recruiting - verified January 2012

Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
Sponsors:   New York Medical College;   New York Medical College
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Aplastic Anemia
Interventions:   Biological: Umbilical Cord Blood Transplantation After Myeloablative Conditioning;   Biological: Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning
Sponsors:   Tufts Medical Center;   Tufts Medical Center
Recruiting - verified May 2012

Conditions:   Solid Tumor;   Adult Central Nervous System Germ Cell Tumor;   Adult Rhabdomyosarcoma;   Childhood Central Nervous System Germ Cell Tumor;   Childhood Soft Tissue Sarcoma;   Ewing Sarcoma;   Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Ovarian Mixed Germ Cell Tumor;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Brain Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Brain Stem Glioma;   Recurrent Childhood Cerebellar Astrocytoma;   Recurrent Childhood Cerebral Astrocytoma;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor;   Recurrent Childhood Visual Pathway and Hypothalamic Glioma;   Recurrent Childhood Visual Pathway Glioma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Extragonadal Germ Cell Tumor;   Recurrent Extragonadal Non-seminomatous Germ Cell Tumor;   Recurrent Malignant Testicular Germ Cell Tumor;   Recurrent Neuroblastoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Wilms Tumor and Other Childhood Kidney Tumors;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: busulfan;   Drug: melphalan;   Drug: topotecan hydrochloride;   Other: laboratory biomarker analysis;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation;   Other: pharmacological study;   Procedure: autologous bone marrow transplantation
Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
Recruiting - verified November 2011

Condition:   Leukemia
Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Procedure: Bone marrow aspiration and biopsy;   Procedure: Apheresis
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition
Interventions:   Biological: alemtuzumab;   Drug: busulfan;   Drug: fludarabine phosphate;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors:   National Cancer Institute (NCI);   Baylor College of Medicine
Recruiting - verified June 2009

Conditions:   Brain and Central Nervous System Tumors;   Kidney Cancer;   Liver Cancer;   Retinoblastoma;   Sarcoma
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: thiotepa;   Procedure: stem cell transplantation;   Procedure: positron emission tomography;   Radiation: tomotherapy;   Radiation: total marrow irradiation;   Drug: Mesna;   Radiation: Whole lung radiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified July 2011

Conditions:   Acute Myeloid Leukemia;   Advanced Myelodysplastic Syndromes
Intervention:   Drug: Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011

Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified January 2012

Conditions:   Multiple Myeloma;   Plasma Cell Leukemia
Interventions:   Drug: Fludarabine/Busulfan x 4 days;   Procedure: stem cell transplant
Sponsors:   University of Michigan Cancer Center;   University of Michigan Cancer Center;   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012

Conditions:   Hodgkin's Disease;   Non Hodgkin's Lymphoma;   Myeloma;   Leukemia;   Myelodysplasia
Intervention:   Drug: Non-myeloablative Stem Cell Transplantation
Sponsors:   Duke University;   Duke University
Recruiting - verified February 2012

Conditions:   CNS Cancer;   CNS BRAIN
Intervention:   Drug: temozolomide followed by high dose busulfan and thiotepa
Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   University of Calgary;   Northwestern University;   Northwestern Memorial Hospital;   University of Wisconsin, Madison;   Massachusetts General Hospital;   Schering-Plough
Recruiting - verified December 2011

Conditions:   Sickle Cell Disease;   Hemoglobin SC
Interventions:   Procedure: ALLOGENEIC BMT/SCT Infusion;   Drug: Busulfan;   Biological: Campath 1H;   Drug: Cyclophosphamide and Mesna
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
Recruiting - verified May 2012

Condition:   Chronic Granulomatous Disease
Interventions:   Drug: Busulfan;   Biological: alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: cyclosporine;   Procedure: stem cell infusion
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
Recruiting - verified May 2012

Condition:   Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: MESNA;   Procedure: Bone marrow or stem cell infusion
Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
Recruiting - verified May 2012

Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
Sponsors:   National Cancer Institute (NCI);   Massachusetts General Hospital
Recruiting - verified April 2008

Conditions:   Myelodysplastic Syndrome;   Leukemia
Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Melphalan
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified May 2012

Conditions:   MUD Transplant;   AlloPBSC;   Congenital Immunodeficiencies;   HLA Matched Transplant;   BMT
Interventions:   Drug: Busulfan;   Drug: Campath-1 H;   Drug: Sirolimus;   Procedure: BMT;   Procedure: Apheresis;   Procedure: Total Body Irradiation;   Procedure: GCSF Injections
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012

Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis
Interventions:   Drug: Busulfan;   Drug: Cytarabine;   Drug: Fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified October 2011

Conditions:   Sickle Cell Disease;   Beta Thalassemia
Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
Sponsors:   Columbia University;   Columbia University
Recruiting - verified October 2011

Conditions:   Myelodysplastic Syndrome;   Leukemia
Interventions:   Drug: Thymoglobulin;   Drug: Busulfan;   Drug: Fludarabine
Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
Recruiting - verified March 2012

Condition:   Chronic Granulomatous Disease
Intervention:   Drug: Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells
Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2011

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011

Condition:   Fanconi Anemia
Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Precancerous Condition
Interventions:   Biological: therapeutic allogeneic lymphocytes;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Radiation: Total Body Irradiation (TBI);   Drug: Granulocyte colony-stimulating factor (G-CSF);   Drug: Phenytoin;   Drug: Methotrexate
Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
Recruiting - verified March 2012

Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
Recruiting - verified April 2012

Conditions:   Leukemia, Lymphocytic, Acute;   AML;   MDS
Interventions:   Procedure: Stem Cell Transplant;   Drug: Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011

Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified March 2012

Conditions:   Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
Interventions:   Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012

Condition:   Juvenile Myelomonocytic Leukemia
Intervention:   Procedure: Stem Cell Transplant
Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
Recruiting - verified November 2011

Conditions:   Childhood Langerhans Cell Histiocytosis;   Fanconi Anemia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methylprednisolone;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   Milton S. Hershey Medical Center
Recruiting - verified October 2008

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   National Cancer Institute (NCI);   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer - EORTC;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified December 2011

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
Recruiting - verified December 2011